Truist raised the firm’s price target on CVS Health (CVS) to $98 from $95 and keeps a Buy rating on the shares. The firm remains bullish on CVS post an upbeat Investor Day highlighting the company’s differentiated collection of assets, strong positioning and opportunities across segments, alongside the announced launch of a centralized engagement platform in FY26, the analyst tells investors in a research note. Brisk cash flow and ongoing balance sheet improvement underpins continued core growth investment, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $95 from $88 at Mizuho
- CVS Health price target raised to $92 from $82 at Baird
- CVS Health price target raised to $93 from $89 at Morgan Stanley
- CVS Health price target raised to $101 from $99 at Piper Sandler
- CVS Health price target raised to $93 from $87 at Barclays